

Framework for Nurse Practitioner Practice in Newfoundland & Labrador





Framework for Nurse Practitioner Practice in Newfoundland & Labrador

Acknowledgements



Table of Contents

Introduction.....	1
Nurse Practitioner Scope of Practice: Interpretation.....	2
Professional Standards for Nurse Practitioners.....	3
Scope of Practice Standards for Nurse Practitioners.....	8
Nurse Practitioner (Primary Health Care) Schedules for Ordering.....	15
Schedule A - Diagnostic Imaging Tests	15
Schedule B - Laboratory and Other Tests	16
Schedule C - Drugs.....	17
References.....	28
Appendix A.....	31



Introduction

Nurse Practitioners are registered nurses with additional educational preparation and experience who possess and demonstrate the competencies to autonomously diagnose, order, and interpret diagnostic tests, prescribe pharmaceuticals and perform specific procedures within their legislated scope of practice (CNPI, 2006).

Nurse practitioners are authorized to perform a range of health services for the diagnosis, treatment and management of clients'¹ health conditions. This entails a high level of autonomy in decision making and accountability for client health outcomes. The *NP Regulations*, under the *RN Act*, support public protection in the provision of NP services. Together the *RN Act*, the *NP Regulations*, and the *ARNNL Framework for Nurse Practitioner Practice in NL* is the regulatory framework governing the practice of NPs in this jurisdiction.

The *ARNNL Framework for NP Practice in NL*, describes the NP scope of practice and establishes the NP professional standards and scope of practice standards². These standards identify minimum expectations for NP practice in Newfoundland and Labrador. NPs are also expected to meet and exceed all of the requirements for registered nurses, as identified in the *ARNNL Standards for Nursing Practice* and *The CNA Code of Ethics for Registered Nurses*.

Standards are authoritative statements that identify the legal and professional expectations for nursing practice. They identify for NPs, the public, government and other stakeholders the desired and achievable level of performance of practice against which actual performance can be measured. Indicators are included for each standard. Indicators illustrate how each standard is applied and met. They are all inclusive in that they describe the range of services NPs are authorized to provide. However, the indicators may be further defined within a setting to address the specific context. In addition to the indicators specific scope of practice standards are further defined through the clinical expectations for practice.

The *ARNNL Professional Standards for Nurse Practitioners* and *Scope of Practice Standards for Nurse Practitioners* apply to all nurse practitioners practicing in Newfoundland & Labrador. However, the *Nurse Practitioner Schedules for Ordering* applies only to NPs working in Primary Health Care roles. NPs working in Specialty roles function according to *practice protocols* developed within the institutional settings and approved in accordance with the *RN Act* and *NP Regulations*.

¹ Client- refers to patient, resident, individual, family, group or community.

² Standards - are authoritative statements that set out the legal and professional basis for nursing practice (CNO, 2002; CRNNS, 2004; ARNNL, 2007).



Nurse Practitioner Scope of Practice: Interpretation

NP Scope of Practice is defined as the activities and functions that NPs are educated and authorized to perform in accordance with the *Registered Nurses Act*, *NP Regulations* and ARNNL Standards. NPs provide comprehensive care within their scope of practice, based on the needs of the client population served. NPs provide health promotion, disease prevention, supportive, curative, rehabilitative and palliative care to individuals, families and communities in a variety of practice settings. NPs are authorized to identify and communicate a diagnosis to a patient or substitute decision maker, order the application of a form of energy (diagnostic imaging tests), order laboratory or other tests, and prescribe drugs.

While legislation, standards and other regulatory controls determine the overall scope of NP practice and the boundaries of practice for NPs as a professional group, other factors influence the practice of the individual NP. These include:

- individual level of competence;
- requirements and policies of the employer;
- needs of clients; and
- practice setting (ARNNL, 2006).

NPs are members of collaborative health care teams and share common ground with physicians and other providers. Within this area of overlap NPs exercise clinical expertise and judgment in the treatment and management of health conditions. Health conditions that fall within the NP scope of practice shall be interpreted to mean diseases and disorders that NPs encounter regularly within the context of their practice. NPs maintain competence within their area of practice and may independently diagnose health conditions for which they are competent. (SRNA, 2006). Competence is attained through education (formal and informal) and experience.



Professional Standards³ for Nurse Practitioners

Standard 1: Self-Regulation and Professional Accountability

The NP is responsible for safe, competent and ethical practice and is accountable to the client, employer, public and the profession.

Indicators:

The NP:

- 1.1 Maintains a current NP license to practice in Newfoundland and Labrador.
- 1.2 Practices in accordance with current legislation, standards and other regulatory controls for NPs.
- 1.3 Is accountable to make client care decisions and acts within his/her legislated scope of practice and level of competence.
- 1.4 Demonstrates a cost effective and efficient approach to the provision of care.
- 1.5 Diagnoses, treats, manages, monitors and evaluates clients' health conditions in accordance with *Scope of Practice Standards for Nurse Practitioners*.
- 1.6 Follows *Scope of Practice Standards for Nurse Practitioners* for communicating diagnoses, ordering diagnostic imaging tests, ordering laboratory or other tests, prescribing drugs or other therapies, performing clinical procedures or consulting with other health professionals.

³ Professional Standards are statements about levels of performance that nurse practitioners are required to achieve in their practice (CRNBC, 2007)



Standard 2: Specialized Body of Knowledge

The NP attains, maintains, and enhances competencies utilizing knowledge of nursing science and integrating knowledge from the pharmaceutical and medical sciences.

Indicators:

The NP:

- 2.1 Has knowledge of and synthesizes the pathophysiology of common acute diseases and injuries, stable chronic conditions, normal health events and emergency health needs encountered in practice.
- 2.2 Has knowledge of and integrates the pharmacokinetics and pharmacodynamics of drugs that are prescribed to manage health conditions encountered in practice.
- 2.3 Has knowledge of and integrates the principles and interventions related to health promotion, injury and disease prevention, cure, rehabilitation, and support in the initial and ongoing management of health conditions encountered in practice.
- 2.4 Has knowledge of and demonstrates the principles of primary health care in practice.
- 2.5 Justifies decisions with reference to current, relevant research findings and other applicable evidence.
- 2.6 Continues to enhance knowledge base as required to provide comprehensive, quality, and evidenced-based care.



Standard 3: Competent Application of Knowledge

The NP uses a systematic approach to collect and synthesize data about the health of the client. The NP applies knowledge and makes clinical judgments in making a diagnosis and in developing, implementing, and evaluating the plan of care.

Indicators:

The NP:

- 3.1 Demonstrates advanced assessment techniques, critical thinking and clinical decision making skills when assessing clients.
- 3.2 Uses a systematic approach to collect and interpret health data through the completion of a focused or comprehensive and holistic health assessment.
- 3.3 Orders diagnostic tests and ensures results are interpreted and acted upon appropriately in the clinical management of health conditions.
- 3.4 Prescribes and monitors the effectiveness of medications and other therapies in the management of clients.
- 3.5 Involves clients in the development, implementation and evaluation of their plan of care.
- 3.6 Makes diagnosis(es) based on the client's health history, findings of health examination and results of any investigations.
- 3.7 Effectively communicates diagnosis(es) to clients and interdisciplinary team members as required.
- 3.8 Uses an evidence-based approach and currently accepted best practice guidelines (if available) in the clinical management of clients.



Standard 4: Professional Interactions and Advocacy

The NP establishes professional relationships with members of the interdisciplinary team and others, and advocates for clients in these relationships.

Indicators:

The NP:

- 4.1 Establishes collaborative relationships and networks with interdisciplinary team members, including physicians, pharmacists, and other health professionals, community agencies and others to meet the needs of clients.⁴
- 4.2 Practices autonomously and collaboratively as a member of an interdisciplinary team.
- 4.3 Initiates consultation with physicians and other members of the interdisciplinary team for an opinion, recommendation or concurrence in the care of clients.
- 4.4 Provides consultation to and accepts referrals from other health providers for clients whose health conditions are within the NP scope of practice.
- 4.5 Refers clients to other health professionals for services when required.

⁴ The reference to physicians and pharmacists in the standards recognizes the partnership of the ARNNL with the College of Physicians and Surgeons of Newfoundland and Labrador and the Newfoundland and Labrador Pharmacy Board as outlined in the RN Act, in order to establish the scope and standards of practice of NPs in NL.



Standard 5: Professional Leadership

The NP provides leadership to enhance client care, the profession, the health system and population health.

Indicators:

The NP:

- 5.1 Contributes to the development of standards, policies, practice guidelines, education and research initiatives in NP practice.
- 5.2 Provides leadership in influencing healthy public policy.
- 5.3 Acts as a role model and mentor to RNs, other NPs and other interdisciplinary team members.
- 5.4 Contributes to advancement of evidence-based practice through initiation and/or participation in research activities, presentations, or publications.



Scope of Practice Standards⁵ for Nurse Practitioners

Standard 1: Collaboration⁶ and Consultation⁷

The NP collaborates with the client, family and other interdisciplinary team members in the provision of care. The NP consults with physicians or other team members to optimize care and ensure the safety of the client.

Indicators:

The NP:

- 1.1 Defines and communicates to the client and members of the interdisciplinary team his/her area of practice and competence.
- 1.2 Promotes and facilitates collaborative partnerships with the client and the interdisciplinary team.
- 1.3 Establishes collaborative relationships with physicians, pharmacists and other interdisciplinary team members.
- 1.4 Initiates consultations with physicians or interdisciplinary team members when the diagnosis and/or treatment plan is beyond the NP's scope of practice or competence. Consults with collaborating physician(s) for the purpose of admitting, discharging and transferring clients from an inpatient or out patient unit..
- 1.5 Involves client in the consultation process starting with the identification of the need for consultation and the desired outcomes.
- 1.6 Documents the request for and outcome of a consultation in a client's permanent health record.
- 1.7 Recognizes the need for and initiates timely, relevant and appropriate referrals⁸ to healthcare professionals or community agencies.
- 1.8 Documents referrals made to healthcare professionals or community agencies in the client's permanent health record.

⁵ Scope of Practice Standards - set out standards, indicators, clinical expectations related to the scope of practice for nurse practitioners.

⁶ Collaboration - means a nurse practitioner working together with a client and one or more interdisciplinary team members to achieve a common goal for the client's outcome of care.

⁷ Consultation - to seek advice or information from a physician or other interdisciplinary team member usually on a more immediate or urgent basis.

⁸ Referral - to request the services of another health professional to treat/care for a client.



Clinical Expectations for Consultation with a Physician:

1. NPs consult with physicians when the expertise of a physician is required to diagnose and/or manage a client's health condition. The level of physician involvement as a result of the consultation will be one of the following:
 - a. The physician provides an opinion and recommendation to the NP who continues to have primary responsibility for the health of the client, or
 - b. The physician assumes concurrent responsibility for some aspects of the care and the physician and NP jointly clarify who is assuming responsibility for the overall coordination of care and various aspects of the client's care, or
 - c. The care of the client is referred (transferred) to the physician who then assumes responsibility for the client (CRNBC, 2007).
2. The NP may consult with or refer to a specialist physician when required, and this consultation or referral shall be communicated to appropriate physicians and members of the interdisciplinary team.
3. The NP shall consult with a physician when a diagnosis or treatment plan is unclear or beyond the scope of the NP to determine.
4. The NP shall consult with physicians in urgent and emergent situations.
5. The NP shall consult a physician on an annual basis regarding reassessment of a client with a chronic condition.



Standard 2: Prescribing Pharmacological Therapy

The nurse practitioner shall manage and monitor the care of the client population by providing safe, effective, and current pharmacological therapy within the NP's scope of practice.

Indicators:

The NP:

- 2.1 Prescribes pharmacological therapy in accordance with Schedule C of the NP Schedules for Ordering or his/her practice protocols.
- 2.2 Utilizes an authoritative source of evidence-based drug and therapeutic information, to appropriately prescribe drugs in the clinical management of clients.
- 2.3 Prescribes over-the-counter medication for the purpose of accessing a drug payment plan.
- 2.4 Provides client education about prescription and non-prescription drugs including: expected action of the drug, importance of compliance, side effects, potential adverse reactions, possible interactions with food or other drugs, follow-up plan and reporting adverse reactions.
- 2.5 Documents medications (prescribed or discontinued) on the client's permanent health record.
- 2.6 Dispenses specific medications in small quantities in situations where a pharmacist is not available or accessible and /or it is in the best interest of the client.
- 2.7 In accordance with the federal *Food and Drug Act*⁹, shall not distribute pharmaceutical drug samples.

⁹ *Food and Drug Act* - does not list nurse practitioners in section C.01.048 or C.01.049 as a recipient or distributor of drug samples. It includes only physicians, dentists, veterinary surgeons and pharmacists. Nurse practitioners shall not accept or dispense drug samples from manufacturers until the current *Food and Drug Act* is changed.

**Clinical expectations for completing a prescription:**

1. Completes a legal prescription accurately and completely according to the Pharmacy Act and regulations and other relevant legislation, standards and policies. Prescriptions must include:
 - a. date;
 - b. client identifier (name, MCP number if required);
 - c. address (if known);
 - d. name, strength, dose and quantity of prescribed drug;
 - e. directions for use; including frequency, the route and duration of treatment;
 - f. number of refills; and
 - g. name, address, designation RN NP, registration number and signature of prescriber.
2. The prescription pads must include the following information: NP's name, registration number and printed business address.
3. NPs working in healthcare facilities shall follow organizational guidelines for writing prescriptions for inpatients/residents and outpatients.
4. NPs may prescribe using written, faxed or electronic prescriptions. Under extenuating circumstances NPs may telephone a prescription to a pharmacist on behalf of a client.
5. A prescription may be transmitted by facsimile (fax) to a pharmacy, in accordance with the Newfoundland and Labrador Pharmacy Board Standards of Pharmacy Practice provided that the following requirements are met:
 - a. the prescription must be sent only to pharmacy of the client's choice with no intervening person having access to the prescription authorization.
 - b. the prescription must be sent directly from the health institution or the prescriber's office or from another location providing that the pharmacist is confident of the prescriber's legitimacy.
 - c. the prescription must include all information listed above in addition must include:
 - i. date and time of transmission
 - ii. name and fax number of the pharmacy intended to receive the transmission
 - iii. a signed certification that the prescription represents the original of the prescription drug order, the addressee is the only recipient and there are no others and the original prescription is invalidated such that it cannot be reissued.
6. NPs document drugs they prescribe or discontinue on the client's permanent health record.
7. Do not prescribe for family members, close friends or oneself when another nurse practitioner or physician is available.



Standard 3: Prescribing non-pharmacological therapy

The NP will manage and monitor the care of the client population by providing safe and effective non-pharmacological therapy within the NP's scope of practice.

Indicators:

The NP:

- 3.1 Engages in evidence-based prescribing and considers best practice guidelines and other relevant guidelines when recommending non-pharmacological therapy.
- 3.2 Provides client education about therapies including: expected action, importance of compliance, side effects, potential adverse reactions, and follow-up plan.
- 3.3 Documents therapies prescribed or discontinued on the client's permanent health record.
- 3.4 Prescribes over-the-counter therapies for the purpose of accessing an insurance or other payment plan.

¹⁰ Non-pharmacological - refers to orthotic aids, medical devices, medical supplies and/or other therapies.



Standard 4: Diagnosing and diagnostic services

NPs diagnose and manage common acute and chronic diseases, disorders and conditions within the limits of the NP's competence and scope of practice.

Indicators:

The NP:

- 4.1 Performs a comprehensive health assessment and analyzes data from multiple sources to formulate a diagnosis or differential diagnosis of a health condition.
- 4.2 Communicates health assessment findings and differential diagnosis and discusses prognosis and treatment options with the client.
- 4.3 Orders diagnostic imaging tests, laboratory and other tests when clinically indicated in accordance with Schedules A and B, or his/her practice protocols.
- 4.4 Ensures that diagnostic tests are interpreted and results are acted upon in an appropriate and timely manner.
- 4.5 Documents all diagnostic tests ordered and/or discontinued on the client's permanent health record.



Standard 5: Performing Clinical Procedures

The NP can perform non-invasive and invasive procedures for which competence is attained and maintained, to assess, restore, regain or maintain physiological stability of clients.

Indicators:

The NP:

- 5.1 Demonstrates the knowledge, skill and judgment to perform the procedure safely, effectively and ethically.
- 5.2 Obtains informed consent from clients prior to performing procedures.
- 5.3 Considers the known risks and benefits to the client, the probable outcome, and ensures safeguards and resources are available to manage outcomes.
- 5.4 Documents procedures in the client's permanent health record.



Nurse Practitioner - Primary Health Care (NP-PHC) Schedules for Ordering

Schedule A

Diagnostic Imaging Tests

NPs in the province of Newfoundland and Labrador are authorized to order diagnostic imaging tests within their scope of practice with the following exceptions or as otherwise authorized by organizational policy:

1. Magnetic Resonance Imaging (MRI)
2. Computerized Tomography (CT) Scans



Schedule B

Laboratory and Other Tests

NPs in the province of Newfoundland and Labrador are authorized to order laboratory and other tests in accordance with their scopes of practice as follows:

Laboratory Tests:

Biochemistry

Cytology/Pathology

Hematology

Immunology

Microbiology

Therapeutic Drug Monitoring

Virology

Other Specific Tests

Additional tests required by the client population may include, but are not limited to, Holter monitoring, Spirometry, ECG, Pulse Oximetry.



Schedule C

Drugs

NPs-PHC in the province of Newfoundland and Labrador are authorized to order drugs according to therapeutic classes listed in the table below. NPs prescribe in accordance with the *RN Act*, the *NP Regulations*, the *Pharmacy Act*, the *ARNNL NP Standards* and the federal *Food and Drug Act and Regulations*. Under the federal *Controlled Drugs and Substances Act* NPs do not have authority to prescribe narcotics or controlled drugs. The federal regulations are currently under review. The NP Standards stipulate that NPs are accountable for their prescribing decisions and must always act within their level of competence and scope of practice.

The American Hospital Formulary Services (AHFS) Pharmacologic Therapeutic Classification is a system that organizes drugs into therapeutic classes. This classification system is widely used internationally. All therapeutic classes and subclasses have unique numbers so that they can be readily identified. (Please refer to the Appendix for an outline of the AHFS classification system). Not all therapeutic classes in the AHFS system are approved for NP prescribing.

The table below is based on the American Hospital Formulary Services (AHFS) system and contains three columns. The first column lists the therapeutic classes (with identification code number) from which NPs are authorized to prescribe. The second column outlines the subclasses that NPs are authorized to prescribe and there are some drugs to which conditions apply. The third column lists the conditions under which certain drugs can be prescribed.



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Antihistamine Drugs 4:00	First Generation Antihistamines 4:04 Ethanolamine Derivatives 4:04.04 Ethylenediamine Derivatives 4:04.08 Phenothiazine Derivatives 4:04.12 Piperazine Derivatives 4:04.16 Propylamine Derivatives 4:04.20 Miscellaneous Derivatives 4:04.92 Second Generation Antihistamines 4:08 Other Antihistamines 4:92	None
Anti-infective Drugs 8:00	Anthelmintics 8:08 Antibacterials 8:12 Aminoglycosides 8:12.02 Cephalosporins 8:12.06 Miscellaneous Beta-Lactams 8:12.07 Chloramphenicol 8:12.08 Macrolides 8:12.12 Penicillins 8:12.16 Quinolones 8:12.18 Sulfonamides 8:12.20 Tetracyclines 8:12.24 Miscellaneous Antibacterials 8:12.28 Antifungals 8:14 Allylamines 8:14.04 Azoles 8:14.08 Echinocandins 8:14.16 Polyenes 8:14.28 Pyrimidines 8:14.32 Miscellaneous Antifungals 8:14.92 Antimycobacterials 8:16 Antituberculosis Agents 8:16.04 (see Conditions) Miscellaneous Antimycobacterials 8:16.92 Antivirals 8:18 Adamantanes 8:18.04 Antiretrovirals 8:18.08 (see Conditions) Interferons 8:18.20 Monoclonal Antibodies 8:18.24 Neuraminidase Inhibitors 8:18.28 Nucleosides and Nucleotides 8:18.32 Miscellaneous Antivirals 8:18.92 Antiprotozoals 8:30 Amebicides 8:30.04 Antimalarials 8:30.08 Miscellaneous Antiprotozoals 8:30.92 Urinary Anti-Infectives 8:36 Miscellaneous Anti-Infectives 8:92	Antituberculosis Agents 8:16.04 (for continuation of therapy only) Antiretrovirals 8:18.08 (for continuation of therapy only)



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Anti-neoplastic Drugs 10:00	Only two agents from this class are approved (See Conditions)	Methotrexate (for inflammatory disease only) Tamoxifen (for continuation of therapy only)
Autonomic Drugs 12:00	Parasympathomimetic (Cholinergic) Agents 12:04 Anticholinergic Agents 12:08 Anti-Parkinsonian Agents 12:08.04 (see Conditions) Antimuscarinics/Antispasmodics 12:08.08 Sympathomimetic (Adrenergic) Agents 12:12 Alpha - Adrenergic Agonists 12:12.04 Beta - Adrenergic Agonists 12:12.08 Alpha & Beta - Adrenergic Agonists 12:12.12 Sympatholytic (Adrenergic Blocking) Agents 12:16 Centrally Acting Skeletal Muscle Relaxants 12:20.04 Miscellaneous Autonomic Drugs, 12:92	Anti-Parkinsonian Agents 12:08.04 (for continuation of therapy only)
Blood Formation, Coagulation, and Thrombosis 20:00	Antianemia Drugs 20:04 Iron Preparations 20:04.04 Liver and Stomach Preparations 20:04.08 Antithrombotic Agents 20:12 Anticoagulants 20:12.04 (See Conditions) Coagulants 20:12.12 Platelet Aggregation Inhibitors 20:12.18 (See Conditions) Hematopoietic Agents 20:16 Hemorrhologic Agents 20:24 Antihemorrhagic Agents 20:28 Antiheparin Agents 20:28.08 Hemostatics 20:28.16	Anticoagulants 20:12.04 (for continuation of therapy or adjustment of dosage) Platelet Aggregation Inhibitors 20:12.18 (for continuation of therapy)
Centrally Acting Skeletal Muscle Relaxants 20:08.04	All	



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
<p>Cardiovascular (CV) Drugs 24:00</p>	<p>Cardiac Drugs 24:04 Anti-arrhythmics 24:04.04 (see Conditions) Cardiotonic Agents 24:04.08 Cardiac Drugs, Miscellaneous 24:04.92</p> <p>Antilipemic Agents 24:06 Bile Acid Sequestrants 24:06.04 Cholesterol Absorption Inhibitors 24:06.05 Fibric Acid Derivatives 24:06.06 HMG-CoA Reductase Inhibitors 24:06.08 Antilipemic, Miscellaneous 24:06.92</p> <p>Hypotensive Agents 24:08 Alpha - Adrenergic Blocking Agents 24:08.04 Beta - Adrenergic Blocking Agents 24:08.08 Calcium-Channel Blocking Agents 24:08.12 (see conditions) Central Alpha Agonists 24:08.16 Direct Vasodilators 24:08.20 Diuretics 24:08.24 Peripheral Adrenergic Inhibitors 24:08.32 Renin-Angiotensin-Aldosterone System Inhibitors 24:08.44 (see conditions) Hypotensive Agents, Miscellaneous 24:08.92</p> <p>Vasodilating Agents 24:12 Nitrates and Nitrites 24:12.08 Phosphodiesterase Inhibitors 24:12.12 Vasodilating Agents, Miscellaneous 24:12.92</p> <p>Sclerosing Agents 24:16</p> <p>Alpha-Adrenergic Blocking Agents 24:20</p> <p>Beta-Adrenergic Blocking Agents 24:24</p> <p>Calcium Channel Blocking Agents 24:28 (see conditions) Dihydropyridines 24:28.08 Calcium Channel Blocking Agents, Miscellaneous 24:28.92</p> <p>Renin-Angiotensin-Aldosterone System Inhibitors 24:32 (see conditions) Angiotensin-Converting Enzyme Inhibitors 24:32.04 Angiotensin II Receptor Antagonists 24:32.08 Mineralocorticoid (Aldosterone) Receptor Antagonists 24:32.20</p>	<p>Anti-arrhythmics 24:04.04 (for continuation of therapy only)</p> <p>Calcium Channel Blocking Agents 24:08.12 EKG must be verified as normal</p> <p>Renin-Angiotensin-Aldosterone System Inhibitors 24:08.44 Must monitor renal function pretreatment and ongoing.</p>



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
<p>Central Nervous System Agents 28:00</p>	<p>Analgesics and Antipyretics 28:08 Non- Steroidal Anti-inflammatory Agents 28:08.04 Analgesics and Antipyretics, Miscellaneous 28:08.92</p> <p>Anticonvulsants 28:12 Hydantoins 28:12.12 Oxazolidinediones 28:12.16 Succinimides 28:12.20 Anticonvulsants, Miscellaneous 28:12:92 (see Conditions)</p> <p>Psychotherapeutic Agents 28:16 Antidepressants 28:16.04 (see Conditions) Antipsychotics 28:16.08 Psychotherapeutic Agents, Miscellaneous 28:16.92</p> <p>Anorexigenic Agents and Respiratory and Cerebral Stimulants 28:20 Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous 28:20:92</p> <p>Anxiolytics, Sedatives and Hypnotics 28:24 Miscellaneous Anxiolytics, Sedatives and Hypnotics 28:24.92</p> <p>Antimanic Agents 28:28</p> <p>Antimigraine Agents 28:32 Selective Serotonin Agonists 28:32.28 Antimigraine Agents, Miscellaneous 28:32.92</p> <p>Antiparkinsonian Agents 28:36 (See conditions) Adamantanes 28:36.04 Anticholinergic Agents 28:36.08 Catechol-O-Methyltransferase (COMT) Inhibitors 28:36.12 Dopamine Precursors 28:36.16 Dopamine Receptor Agonists 28:36.20 Monamine Oxidase B inhibitors 28:36.32</p> <p>Central Nervous System Agents, Miscellaneous 28:92</p>	<p>Anticonvulsants, Miscellaneous 28:12.92 NPs cannot prescribe agents containing Controlled substances</p> <p>Antidepressants 28:16.04 NPs cannot prescribe Monoamine Oxidase Inhibitors 28:16.04.12</p> <p>Antiparkinsonian Agents 28:36 For continuation of therapy only</p>
<p>Contraceptives (foams and devices) 32:00</p>	<p>All</p>	<p>None</p>



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Electrolytic, Caloric, and Water Balance 40:00	Ammonia Detoxicants 40:10 (See conditions) Replacement Preparations 40:12 Ion-removing Agents 40:18 Sodium-removing Agents 40:18.16 Calcium-removing Agents 40:18.17 Potassium-removing Agents 40:18.18 Phosphate-removing Agents 40:18.19 Ion-removing Agents, Other 40:18.92 Caloric Agents 40:20 Salt and Sugar Substitutes 40:24 Diuretics 40:28 Carbonic Anhydrase Inhibitors 40:28.04 Loop Diuretics 40:28.08 Osmotic Diuretics 40:28.12 Potassium-sparing Diuretics 40:28.16 Thiazide Diuretics 40:28.20 Thiazide-like Diuretics 40:28.24 Diuretics, Miscellaneous 40:28.92 Irrigating Solutions 40:36 Uricosuric Agents 40:40	Ammonia Detoxicants 40:10 NPs authorized to prescribe Lactulose 40:10.
Enzymes 44:00	Enzymes 44:00	
Respiratory Tract Agents 48:00	See Conditions Antihistamines 48:04 First Generation Antihistamines 48:04.04 Second Generation Antihistamines 48:04.08 Antitussives 48:08, Anti-inflammatory Agents 48:10 Corticosteroids 48:10.08 Leukotriene modifiers 48:10.24 (see conditions) Bronchodilators 48:12 Adrenergic Agents 48:12.04 Anticholinergic Agents 48:12.08 Expectorants 48:16 Mucolytic Agents 48:24 Vasodilating Agents 48:48	NPs cannot prescribe agents containing narcotics/controlled substances Leukotriene modifiers 48:10:24 (for continuation of therapy only)



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Eye, Ear, Nose, and Throat (EENT) Preparations 52:00	Antiallergic Agents 52:02 Anti-infectives 52:04 Antibacterials 52:04.04 Antifungals 52:04.16 Antivirals 52:04.20 Anti-infectives, Miscellaneous 52:04.92 Anti-inflammatory Agents 52:08 Corticosteroids 52:08.08 (See Conditions) Nonsteroidal Anti-inflammatory Agents 52:08.20 Anti-inflammatory Agents, Miscellaneous 52:08.92 Contact Lens Solutions 52:12 Mydriatics 52:24 (see conditions) Mouthwashes and Gargles 52:28 Vasoconstrictors 52:32 Antiglaucoma Agents 52:40 (See conditions) Alpha - Adrenergic Agonists 52:40.04 Beta - Adrenergic Agents 52:40.08 Carbonic Anhydrase Inhibitors 52:40.12 Miotics 52:40.20 Osmotic Agents 52:40.24 Prostaglandin Analogs 52:40.28 Antiglaucoma Agents, Miscellaneous 52:40.92 EENT Drugs, Miscellaneous 52:92	Corticosteroids 52:08:08 Cannot prescribe Ophthalmological steroids Mydriatics 52:24 (For continuation of therapy only) Antiglaucoma agents 52:40 (For continuation of therapy only)
Gastrointestinal Drugs 56:00	Antacids and Adsorbents 56:04 Antidiarrhea Agents 56:08 (see conditions) Antiflatulents 56:10 Cathartics and Laxatives 56:12 Cholelitholytic Agents 56:14 Digestants 56:16 Emetics 56:20 Antiemetics 56:22 Antihistamines 56:22.08 5-HT ₃ Receptor Antagonist 56:22.20 Antiemetics, Miscellaneous 56:22.92 Lipotropic Agents 56:24 Antiulcer Agents and Acid Suppressants 56:28 Histamine H ₂ -Antagonists 56:28.12 Prostaglandins 56:28.28 Protectants 56:28.32 Proton pump Inhibitors 56:28.36 Prokinetic Agents 56:32 Anti-inflammatory Agents 56:36	Antidiarrhea agents 56:08 NPs cannot prescribe agents containing narcotics /controlled substances.
Gold Compounds 60:00	Gold Compounds 60:00 (See Conditions)	For continuation of therapy or adjustment of dosage only



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Heavy Metal Antagonists 64:00	Heavy Metal Antagonists 64:00 (See Conditions)	For continuation of therapy or adjustment of dosage only
Hormones and Synthetic Substitutes 68:00	<p>Adrenals 68:04</p> <p>Contraceptives 68:12</p> <p>Estrogens and Antiestrogens 68:16</p> <p>Estrogens 68:16:04</p> <p>Antidiabetic Agents 68:20</p> <p>Alpha-Glucosidase Inhibitors 68:20.02</p> <p>Amylinomimetics 68:20.03</p> <p>Biguanides 68:20.04</p> <p>Dipeptidyl Peptidase IV (DDP-4) Inhibitors 68:20.05</p> <p>Incretin Mimetics 68:20.06</p> <p>Insulins 68:20.08 (see conditions)</p> <p>Meglitinides 68:20.16</p> <p>Sulfonylureas 68:20.20</p> <p>Thiazolidinediones 68:20.28</p> <p>Antidiabetic Agents, Miscellaneous, 68:20.92</p> <p>Antihypoglycemic Agents 68:22</p> <p>Glycogenolytic Agents 68:22.12</p> <p>Antihypoglycemic Agents, Miscellaneous 68:22.92</p> <p>Parathyroid 68:24 (See Conditions)</p> <p>Pituitary 68:28 (See Conditions)</p> <p>Thyroid and Antithyroid Agents 68:36</p> <p>Thyroid Agents 68:36.04</p> <p>Antithyroid Agents 68:36.08 (See Conditions)</p>	<p>Insulins 68:20:08 (NP must consult physician prior to prescribing initial treatment)</p> <p>Parathyroid 68:24 (for continuation of therapy only)</p> <p>Pituitary 68:28 (for continuation of therapy only)</p> <p>Anti-thyroid agents 68:36:08 (for continuation of therapy and adjustment of dosage only).</p>
Serums, Toxoids, and Vaccines 80:00	Serums 80:04 Toxoids 80:08 Vaccines 80:12 (See Conditions)	NPs not permitted to prescribe Yellow Fever Vaccine



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Heavy Metal Antagonists 64:00	Heavy Metal Antagonists 64:00 (See Conditions)	For continuation of therapy or adjustment of dosage only
Hormones and Synthetic Substitutes 68:00	<p>Adrenals 68:04</p> <p>Contraceptives 68:12</p> <p>Estrogens and Antiestrogens 68:16</p> <p>Estrogens 68:16:04</p> <p>Antidiabetic Agents 68:20</p> <p>Alpha-Glucosidase Inhibitors 68:20.02</p> <p>Amylinomimetics 68:20.03</p> <p>Biguanides 68:20.04</p> <p>Dipeptidyl Peptidase IV (DDP-4) Inhibitors 68:20.05</p> <p>Incretin Mimetics 68:20.06</p> <p>Insulins 68:20.08 (see conditions)</p> <p>Meglitinides 68:20.16</p> <p>Sulfonylureas 68:20.20</p> <p>Thiazolidinediones 68:20.28</p> <p>Antidiabetic Agents, Miscellaneous, 68:20.92</p> <p>Antihypoglycemic Agents 68:22</p> <p>Glycogenolytic Agents 68:22.12</p> <p>Antihypoglycemic Agents, Miscellaneous 68:22.92</p> <p>Parathyroid 68:24 (See Conditions)</p> <p>Pituitary 68:28 (See Conditions)</p> <p>Thyroid and Antithyroid Agents 68:36</p> <p>Thyroid Agents 68:36.04</p> <p>Antithyroid Agents 68:36.08 (See Conditions)</p>	<p>Insulins 68:20:08 (NP must consult physician prior to prescribing initial treatment)</p> <p>Parathyroid 68:24 (for continuation of therapy only)</p> <p>Pituitary 68:28 (for continuation of therapy only)</p> <p>Anti-thyroid agents 68:36:08 (for continuation of therapy and adjustment of dosage only).</p>
Serums, Toxoids, and Vaccines 80:00	Serums 80:04 Toxoids 80:08 Vaccines 80:12 (See Conditions)	NPs not permitted to prescribe Yellow Fever Vaccine



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Skin and Mucous Membrane Agents 84:00	Anti-infectives 84:04 Antibacterials 84:04.04 Antivirals 84:04.06 Antifungals 84:04.08 Scabicides and Pediculicides 84:04.12 Miscellaneous Local Anti-infectives 84:04.16 Anti-inflammatory Agents 84:06 (see Conditions) Antipruritics and Local Anesthetics 84:08 Astringents 84:12 Cell Stimulants and Proliferants 84:16 Detergents 84:20 Emoilients, Demulcents and Protectants 84:24 Basic Lotions and Liniments 84:24.04 Basic Oils and other Solvents 84:24.08 Basic ointments and Protectants 84:24.12 Basic Powders and Demulcents 84:24.16 Keratolytic Agents 84:28 Keratoplastic Agents 84:32 Depigmenting and Pigmenting Agents 84:50 Depigmenting Agents 84:50.04 Pigmenting Agents 84:50.06 Sunscreen Agents 84:80 Skin and Mucous Membrane Agents, Miscellaneous 84:92 (see Conditions)	Anti-inflammatory agents 84:06 NPs authorized to prescribe: Beclomethasone dipropionate 0.025% Betamethasone benzoate 0.025% Betamethasone valerate 0.05%, 0.1% Clobetasone butyrate 0.05% Diflucortolone valerate 0.1% Fluocinolone acetonide 0.01%, 0.025% Hydrocortisone valerate 0.2% Mometasone furoate 0.1% Triamcinolone acetonide 0.1% Desonide 0.05% Hydrocortisone 0.5%, 1%, 2.5% Hydrocortisone acetate 0.1%, 1% Methylprednisolone acetate 0.25% (Grey,2003) NPs not permitted to prescribe: Topical Fluorouracil, Isotretinoin
Smooth Muscle Relaxants 86:00	Gastrointestinal Smooth Muscle Relaxants 86:08 Genitourinary Smooth Muscle Relaxants 86:12	None
Vitamins 88:00	Vitamin A 88:04 Vitamin B Complex 88:08 Vitamin C 88:12 Vitamin D 88:16 Vitamin E 88:20 Vitamin K Activity 88:24 Multivitamin Preparations 88:28	None



Therapeutic Class AHFS Identification Code Number	Approved	Conditions
Miscellaneous Therapeutic Agents 92:00	Alcohol Deterrents, Antidotes, Antigout Agents, Bone Resorption Inhibitors Other (See Conditions)	NP must consult physician prior to prescribing initial dose of the following: Biologic response modifiers, Disease Modifying Anti-rheumatic agents, Immunosuppressive agents. 5 alpha Reductase Inhibitors (for continuation of therapy only).
Medical Devices 94:00	?	?
Pharmaceutical Aids 96:00	?	?





References

- American Society of Health System Pharmacists (2005). AHFS drug information. (2004). Bethesda, MD: Author.
- Association of Registered Nurses of Newfoundland and Labrador.(2007). *Standards For Nursing Practice*, St. John's: Author.
- Association of Registered Nurses of Newfoundland and Labrador. (2001). *Registered Nurses Act*. St. John's: Author.
- Association of Registered Nurses of Newfoundland and Labrador.(2007). *The Professional Regulatory Framework for Nurse Practitioners Province of Newfoundland and Labrador*. St. John's: Author.
- Canadian Nurses Association.(2005). *Canadian Nurse Practitioner Core Competency Framework*. Ottawa: Author.
- Canadian Nurses Association.(2002) *Achieving Excellence in Professional Practice: A Guide to Developing and Revising Standards*. Ottawa: Author.
- Canadian Nurses Association.(2002).*The Code of Ethics*. Ottawa: Author.
- Canadian Nurse Practitioner Initiative. (2006). *Nurse Practitioners: The Time Is Now, A Solution to Improving Access and Reducing Wait Times in Canada*. Ottawa: Author
- College and Association of Registered Nurses of Alberta.(2004).*Prescribing and Distributing Guidelines for Nurse Practitioners*. Alberta: Author.
- College of Nurses of Ontario. (2005). *Standards of Practice for Registered Nurses in the Extended Class*. Toronto: Author.
- College of Registered Nurse of British Columbia.(2007). *Scope of Practice for Nurse Practitioners (Family): Standards, Limits and Conditions*. British Columbia: Author.
- College of Registered Nurses of Manitoba.(2005). *Standards of Practice for Registered Nurses on the Extended Practice Register*. Manitoba: Author.
- College of Registered Nurses of Nova Scotia.(2005).*Standards of Practice for Nurse Practitioners*. Halifax: Author.
- Grey, J. (ED). (2003). *Therapeutic Choices* (4th ed.) Ottawa. Canadian Pharmacists Association.
- Newfoundland and Labrador Regulation 65/98. *Nurse Practitioner Regulations under the Registered Nurses Act (2004)*. St. John's: Queen's Printer.



Nurses Association of New Brunswick.(2005).*Nurse Practitioner Competencies and Standards of Practice*. Fredericton: Author.

NP Regulations Review Committee of the Nurse Practitioner Consultative and Approvals Committee. (2005). *Nurse Practitioner Regulations Review Report*. St. John's: Author.

Registered Nurses Association of the Northwest Territories and Nunavut.(2006). *Standards of Nursing Practice For Registered Nurses*. Yellowknife: Author.

Saskatchewan Registered Nurses Association.(2003). *Registered Nurse (Nurse Practitioner) RN (NP), Standards and Core Competencies*. Saskatchewan: Author.

Yukon Registered Nurses Association.(2005).*Standards for Registered Nursing Practice in the Yukon*. Whitehorse: Author.



Appendix A

AHFS Classification

AHFS Pharmacologic-Therapeutic Classification®

4:00 - Antihistamine Drugs

4:04 - First Generation Antihistamines

- 4:04.04 - Ethanolamine Derivatives*
- 4:04.08 - Ethylenediamine Derivatives*
- 4:04.12 - Phenothiazine Derivatives*
- 4:04.16 - Piperazine Derivatives*
- 4:04.20 - Propylamine Derivatives*
- 4:04.92 - Miscellaneous Derivatives*

4:08 - Second Generation Antihistamines

4:92 - Other Antihistamines*

8:00 - Anti-infective Agents

8:08 - Anthelmintics

8:12 - Antibacterials

- 8:12.02 - Aminoglycosides
- 8:12.06 - Cephalosporins
 - 8:12.06.04 - First Generation Cephalosporins
 - 8:12.06.08 - Second Generation Cephalosporins
 - 8:12.06.12 - Third Generation Cephalosporins
 - 8:12.06.16 - Fourth Generation Cephalosporins
- 8:12.07 - Miscellaneous β -Lactams
 - 8:12.07.04 - Carbacephems*
 - 8:12.07.08 - Carbapenems
 - 8:12.07.12 - Cephamycins
 - 8:12.07.16 - Monobactams
- 8:12.08 - Chloramphenicol
- 8:12.12 - Macrolides
 - 8:12.12.04 - Erythromycins
 - 8:12.12.12 - Ketolides
 - 8:12.12.92 - Other Macrolides
- 8:12.16 - Penicillins
 - 8:12.16.04 - Natural Penicillins
 - 8:12.16.08 - Aminopenicillins
 - 8:12.16.12 - Penicillinase-resistant Penicillins
 - 8:12.16.16 - Extended-spectrum Penicillins
- 8:12.18 - Quinolones
- 8:12.20 - Sulfonamides
- 8:12.24 - Tetracyclines
 - 8:12.24.12 - Glycylcyclines
- 8:12.28 - Antibacterials, Miscellaneous
 - 8:12.28.04 - Aminocyclitols
 - 8:12.28.08 - Bacitracins
 - 8:12.28.12 - Cyclic Lipopeptides
 - 8:12.28.16 - Glycopeptides
 - 8:12.28.20 - Lincomycins
 - 8:12.28.24 - Oxazolidinones
 - 8:12.28.28 - Polymyxins
 - 8:12.28.30 - Rifamycins
 - 8:12.28.32 - Streptogramins
 - 8:12.28.92 - Other Miscellaneous Antibacterials*

8:14 - Antifungals

- 8:14.04 - Allylamines
- 8:14.08 - Azoles
- 8:14.16 - Echinocandins

AHFS Drug Information® 2008

- 8:14.28 - Polyenes
- 8:14.32 - Pyrimidines
- 8:14.92 - Antifungals, Miscellaneous

8:16 - Antimycobacterials

- 8:16.04 - Antituberculosis Agents
- 8:16.92 - Antimycobacterials, Miscellaneous

8:18 - Antivirals

- 8:18.04 - Adamantanes
- 8:18.08 - Antiretrovirals
 - 8:18.08.04 - HIV Fusion Inhibitors
 - 8:18.08.08 - HIV Protease Inhibitors
 - 8:18.08.12 - Integrase Inhibitors
 - 8:18.08.16 - Nonnucleoside Reverse Transcriptase Inhibitors
 - 8:18.08.20 - Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
 - 8:18.08.92 - Antiretrovirals, Miscellaneous*
- 8:18.20 - Interferons
- 8:18.24 - Monoclonal Antibodies
- 8:18.28 - Neuraminidase Inhibitors
- 8:18.32 - Nucleosides and Nucleotides
- 8:18.92 - Antivirals, Miscellaneous

8:30 - Antiprotozoals

- 8:30.04 - Amebicides
- 8:30.08 - Antimalarials
- 8:30.92 - Antiprotozoals, Miscellaneous

8:36 - Urinary Anti-infectives

8:92 - Anti-infectives, Miscellaneous*

10:00 - Antineoplastic Agents

12:00 - Autonomic Drugs

12:04 - Parasympathomimetic (Cholinergic) Agents

12:08 - Anticholinergic Agents

- 12:08.04 - Antiparkinsonian Agents*
- 12:08.08 - Antimuscarinics/Antispasmodics

12:12 - Sympathomimetic (Adrenergic) Agents

- 12:12.04 - α -Adrenergic Agonists
- 12:12.08 - β -Adrenergic Agonists
 - 12:12.08.04 - Non-selective β -Adrenergic Agonists
 - 12:12.08.08 - Selective β_1 -Adrenergic Agonists
 - 12:12.08.12 - Selective β_2 -Adrenergic Agonists
- 12:12.12 - α - and β -Adrenergic Agonists

12:16 - Sympatholytic (Adrenergic Blocking) Agents

12:20 - Skeletal Muscle Relaxants

- 12:20.04 - Centrally Acting Skeletal Muscle Relaxants
- 12:20.08 - Direct-acting Skeletal Muscle Relaxants



AHFS Classification

12:20.12 - GABA-derivative Skeletal Muscle Relaxants
12:20.20 - Neuromuscular Blocking Agents
12:20.92 - Skeletal Muscle Relaxants, Miscellaneous
12:92 - Autonomic Drugs, Miscellaneous

16:00 - Blood Derivatives**20:00 - Blood Formation, Coagulation, and Thrombosis**

20:04 - Antianemia Drugs
20:04.04 - Iron Preparations
20:04.08 - Liver and Stomach Preparations*
20:12 - Antithrombotic Agents
20:12.04 - Anticoagulants
20:12.04.08 - Coumarin Derivatives
20:12.04.12 - Direct Thrombin Inhibitors
20:12.04.16 - Heparins
20:12.04.92 - Anticoagulants, Miscellaneous
20:12.18 - Platelet-Aggregation Inhibitors
20:12.20 - Thrombolytic Agents
20:16 - Hematopoietic Agents
20:24 - Hemorrhologic Agents
20:28 - Antihemorrhagic Agents
20:28.08 - Antiheparin Agents
20:28.16 - Hemostatics

24:00 - Cardiovascular Drugs

24:04 - Cardiac Drugs
24:04.04 - Antiarrhythmic Agents
24:04.04.04 - Class Ia Antiarrhythmics
24:04.04.08 - Class Ib Antiarrhythmics
24:04.04.12 - Class Ic Antiarrhythmics
24:04.04.16 - Class II Antiarrhythmics*
24:04.04.20 - Class III Antiarrhythmics
24:04.04.24 - Class IV Antiarrhythmics
24:04.04.92 - Antiarrhythmics, Miscellaneous*
24:04.08 - Cardiotoxic Agents
24:04.92 - Cardiac Drugs, Miscellaneous
24:06 - Antilipemic Agents
24:06.04 - Bile Acid Sequestrants
24:06.05 - Cholesterol Absorption Inhibitors
24:06.06 - Fibrin Acid Derivatives
24:06.08 - HMG-CoA Reductase Inhibitors
24:06.92 - Antilipemic Agents, Miscellaneous
24:08 - Hypotensive Agents
24:08.04 - α -Adrenergic Blocking Agents*
24:08.08 - β -Adrenergic Blocking Agents*
24:08.12 - Calcium-Channel Blocking Agents*
24:08.12.08 - Dihydropyridines*
24:08.12.92 - Calcium-Channel Blocking Agents, Miscellaneous*
24:08.16 - Central α -Agonists

24:08.20 - Direct Vasodilators
24:08.24 - Diuretics*
24:08.24.04 - Carbonic Anhydrase Inhibitors*
24:08.24.08 - Loop Diuretics*
24:08.24.12 - Osmotic Diuretics*
24:08.24.16 - Potassium-sparing Diuretics*
24:08.24.20 - Thiazide Diuretics*
24:08.24.24 - Thiazide-like Diuretics*
24:08.24.92 - Diuretics, Miscellaneous*
24:08.32 - Peripheral Adrenergic Inhibitors
24:08.44 - Renin-Angiotensin-Aldosterone System Inhibitors*
24:08.44.04 - Angiotensin-Converting Enzyme Inhibitors*
24:08.44.08 - Angiotensin II Receptor Antagonists*
24:08.44.20 - Mineralocorticoid (Aldosterone) Receptor Antagonists*
24:08.92 - Hypotensive Agents, Miscellaneous*
24:12 - Vasodilating Agents
24:12.08 - Nitrates and Nitrites
24:12.12 - Phosphodiesterase Inhibitors
24:12.92 - Vasodilating Agents, Miscellaneous
24:16 - Sclerosing Agents
24:20 - α -Adrenergic Blocking Agents
24:24 - β -Adrenergic Blocking Agents
24:28 - Calcium-Channel Blocking Agents
24:28.08 - Dihydropyridines
24:28.92 - Calcium-Channel Blocking Agents, Miscellaneous
24:32 - Renin-Angiotensin-Aldosterone System Inhibitors
24:32.04 - Angiotensin-Converting Enzyme Inhibitors
24:32.08 - Angiotensin II Receptor Antagonists
24:32.20 - Mineralocorticoid (Aldosterone) Receptor Antagonists
24:32.40 - Renin Inhibitors

28:00 - Central Nervous System Agents

28:04 - General Anesthetics
28:04.04 - Barbiturates
28:04.16 - Inhalation Anesthetics*
28:04.92 - General Anesthetics, Miscellaneous
28:08 - Analgesics and Antipyretics
28:08.04 - Nonsteroidal Anti-inflammatory Agents
28:08.04.08 - Cyclooxygenase-2 (COX-2) Inhibitors
28:08.04.24 - Salicylates
28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents
28:08.08 - Opiate Agonists
28:08.12 - Opiate Partial Agonists
28:08.92 - Analgesics and Antipyretics, Miscellaneous
28:10 - Opiate Antagonists
28:12 - Anticonvulsants
28:12.04 - Barbiturates



AHFS Classification

- 28:12.08 - Benzodiazepines
- 28:12.12 - Hydantoins
- 28:12.16 - Oxazolidinones*
- 28:12.20 - Succinimides
- 28:12.92 - Anticonvulsants, Miscellaneous
- 28:16 - Psychotherapeutic Agents**
- 28:16.04 - Antidepressants
 - 28:16.04.12 - Monoamine Oxidase Inhibitors
 - 28:16.04.16 - Selective Serotonin- and Norepinephrine-reuptake Inhibitors
 - 28:16.04.20 - Selective-serotonin Reuptake Inhibitors
 - 28:16.04.24 - Serotonin Modulators
 - 28:16.04.28 - Tricyclics and Other Norepinephrine-reuptake Inhibitors
 - 28:16.04.92 - Antidepressants, Miscellaneous
- 28:16.08 - Antipsychotics
 - 28:16.08.04 - Atypical Antipsychotics
 - 28:16.08.08 - Butyrophenones
 - 28:16.08.24 - Phenothiazines
 - 28:16.08.32 - Thioxanthenes
 - 28:16.08.92 - Antipsychotics, Miscellaneous
- 28:16.92 - Psychotherapeutic Agents, Miscellaneous*
- 28:20 - Anorexigenic Agents and Respiratory and Cerebral Stimulants**
- 28:20.04 - Amphetamines
- 28:20.92 - Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous
- 28:24 - Anxiolytics, Sedatives, and Hypnotics**
- 28:24.04 - Barbiturates
- 28:24.08 - Benzodiazepines
- 28:24.92 - Anxiolytics, Sedatives, and Hypnotics; Miscellaneous
- 28:28 - Antimanic Agents**
- 28:32 - Antimigraine Agents**
- 28:32.28 - Selective Serotonin Agonists
- 28:32.92 - Antimigraine Agents, Miscellaneous*
- 28:36 - Antiparkinsonian Agents**
- 28:36.04 - Adamantanes
- 28:36.08 - Anticholinergic Agents
- 28:36.12 - Catechol-O-Methyltransferase (COMT) Inhibitors
- 28:36.16 - Dopamine Precursors
- 28:36.20 - Dopamine Receptor Agonists
 - 28:36.20.04 - Ergot-derivative Dopamine Receptor Agonists
 - 28:36.20.08 - Nonergot-derivative Dopamine Receptor Agonists
- 28:36.32 - Monoamine Oxidase B Inhibitors
- 28:92 - Central Nervous System Agents, Miscellaneous**

32:00 - Contraceptives (foams, devices)*

34:00 - Dental Agents*

36:00 - Diagnostic Agents

- 36:04 - Adrenocortical Insufficiency§
- 36:08 - Amyloidosis*
- 36:10 - Appendicitis*
- 36:12 - Blood Volume*
- 36:16 - Brucellosis*
- 36:18 - Cardiac Function*
- 36:24 - Circulation Time*
- 36:26 - Diabetes Mellitus*
- 36:28 - Diphtheria*
- 36:30 - Drug Hypersensitivity§
- 36:32 - Fungi§
- 36:34 - Gallbladder Function§
- 36:36 - Gastric Function*
- 36:38 - Intestinal Absorption§
- 36:40 - Kidney Function§
- 36:44 - Liver Function§
- 36:48 - Lymphogranuloma Venereum*
- 36:52 - Mumps§
- 36:56 - Myasthenia Gravis§
- 36:58 - Ocular Disorders*
- 36:60 - Thyroid Function*
- 36:61 - Pancreatic Function§
- 36:62 - Phenylketonuria*
- 36:64 - Pheochromocytoma*
- 36:66 - Pituitary Function§
- 36:68 - Roentgenography*
- 36:72 - Scarlet Fever*
- 36:76 - Sweating*
- 36:80 - Trichinosis*
- 36:84 - Tuberculosis
- 36:88 - Urine and Feces Contents*
 - 36:88.12 - Ketones*
 - 36:88.20 - Occult Blood*
 - 36:88.24 - pH*
 - 36:88.28 - Protein*
 - 36:88.40 - Sugar*

38:00 - Disinfectants (for agents used on objects other than skin)*

40:00 - Electrolytic, Caloric, and Water Balance

- 40:04 - Acidifying Agents
- 40:08 - Alkalinizing Agents
- 40:10 - Ammonia Detoxicants
- 40:12 - Replacement Preparations
- 40:18 - Ion-removing Agents



AHFS Classification

40:18.16 - Sodium-removing Agents*
40:18.17 - Calcium-removing Agents
40:18.18 - Potassium-removing Agents
40:18.19 - Phosphate-removing Agents
40:18.92 - Other Ion-removing Agents
40:20 - Caloric Agents
40:24 - Salt and Sugar Substitutes*
40:28 - Diuretics
40:28.04 - Carbonic Anhydrase Inhibitors*
40:28.08 - Loop Diuretics
40:28.12 - Osmotic Diuretics
40:28.16 - Potassium-sparing Diuretics
40:28.20 - Thiazide Diuretics
40:28.24 - Thiazide-like Diuretics
40:28.92 - Diuretics, Miscellaneous
40:36 - Irrigating Solutions§
40:40 - Uricosuric Agents

44:00 - Enzymes§**48:00 - Respiratory Tract Agents**

48:04 - Antihistamines
48:04.04 - First Generation Antihistamines*
48:04.08 - Second Generation Antihistamines*
48:08 - Antitussives
48:10 - Anti-inflammatory Agents
48:10.08 - Corticosteroids*
48:10.08.04 - Nasal Preparations*
48:10.08.08 - Orally Inhaled Preparations*
48:10.24 - Leukotriene Modifiers
48:10.32 - Mast-cell Stabilizers
48:12 - Bronchodilators*
48:12.04 - Adrenergic Agents*
48:12.04.08 - Non-selective β -Adrenergic Agonists*
48:12.04.12 - Selective β_2 -Adrenergic Agonists*
48:12.04.16 - α - and β -Adrenergic Agonists*
48:12.08 - Anticholinergic Agents*
48:12.12 - Xanthine Derivatives*
48:16 - Expectorants
48:24 - Mucolytic Agents*
48:36 - Pulmonary Surfactants§
48:48 - Vasodilating Agents*
48:92 - Respiratory Agents, Miscellaneous

52:00 - Eye, Ear, Nose, and Throat (EENT) Preparations

52:02 - Antiallergic Agents
52:04 - Anti-infectives
52:04.04 - Antibacterials
52:04.16 - Antifungals
52:04.20 - Antivirals
52:04.92 - Anti-infectives, Miscellaneous
52:08 - Anti-inflammatory Agents

52:08.08 - Corticosteroids
52:08.20 - Nonsteroidal Anti-inflammatory Agents
52:08.92 - Anti-inflammatory Agents, Miscellaneous
52:12 - Contact Lens Solutions*
52:16 - Local Anesthetics
52:24 - Mydriatics
52:28 - Mouthwashes and Gargles
52:32 - Vasoconstrictors
52:40 - Antiglaucoma Agents
52:40.04 - α -Adrenergic Agonists
52:40.08 - β -Adrenergic Agents
52:40.12 - Carbonic Anhydrase Inhibitors
52:40.20 - Miotics
52:40.24 - Osmotic Agents*
52:40.28 - Prostaglandin Analogs
52:40.92 - Antiglaucoma Agents, Miscellaneous*
52:92 - EENT Drugs, Miscellaneous

56:00 - Gastrointestinal Drugs

56:04 - Antacids and Adsorbents
56:08 - Antidiarrhea Agents
56:10 - Antiflatulents
56:12 - Cathartics and Laxatives
56:14 - Cholelitholytic Agents*
56:16 - Digestants
56:20 - Emetics
56:22 - Antiemetics
56:22.08 - Antihistamines
56:22.20 - 5-HT₃ Receptor Antagonists
56:22.92 - Antiemetics, Miscellaneous
56:24 - Lipotropic Agents*
56:28 - Antiulcer Agents and Acid Suppressants
56:28.12 - Histamine H₂-Antagonists
56:28.28 - Prostaglandins
56:28.32 - Protectants
56:28.36 - Proton-pump Inhibitors
56:32 - Prokinetic Agents§
56:36 - Anti-inflammatory Agents
56:92 - GI Drugs, Miscellaneous

60:00 - Gold Compounds§**64:00 - Heavy Metal Antagonists§**

68:00 - Hormones and Synthetic Substitutes
68:04 - Adrenals
68:08 - Androgens
68:12 - Contraceptives



AHFS Classification

- 68:16 - Estrogens and Antiestrogens**
 - 68:16.04 - Estrogens
 - 68:16.12 - Estrogen Agonists-Antagonists
- 68:18 - Gonadotropins**
- 68:20 - Antidiabetic Agents**
 - 68:20.02 - α -Glucosidase Inhibitors
 - 68:20.03 - Amylinomimetics
 - 68:20.04 - Biguanides
 - 68:20.05 - Dipeptidyl Peptidase IV (DDP-4) Inhibitors
 - 68:20.06 - Incretin Mimetics
 - 68:20.08 - Insulins
 - 68:20.16 - Meglitinides
 - 68:20.20 - Sulfonylureas
 - 68:20.28 - Thiazolidinediones
 - 68:20.92 - Antidiabetic Agents, Miscellaneous*
- 68:22 - Antihypoglycemic Agents**
 - 68:22.12 - Glycogenolytic Agents
 - 68:22.92 - Antihypoglycemic Agents, Miscellaneous*
- 68:24 - Parathyroid**
- 68:28 - Pituitary**
- 68:30 - Somatotropin Agonists and Antagonists**
 - 68:30.04 - Somatotropin Agonists
 - 68:30.08 - Somatotropin Antagonists
- 68:32 - Progestins**
- 68:34 - Other Corpus Luteum Hormones***
- 68:36 - Thyroid and Antithyroid Agents**
 - 68:36.04 - Thyroid Agents
 - 68:36.08 - Antithyroid Agents

- 72:00 - Local Anesthetics**

- 76:00 - Oxytocics**

- 78:00 - Radioactive Agents***

- 80:00 - Serums, Toxoids, and Vaccines**
 - 80:04 - Serums
 - 80:08 - Toxoids
 - 80:12 - Vaccines

- 84:00 - Skin and Mucous Membrane Agents**
 - 84:04 - Anti-infectives**
 - 84:04.04 - Antibacterials
 - 84:04.06 - Antivirals
 - 84:04.08 - Antifungals
 - 84:04.08.04 - Allylamines
 - 84:04.08.08 - Azoles
 - 84:04.08.12 - Benzylamines
 - 84:04.08.16 - Echinocandins*
 - 84:04.08.20 - Hydroxypyridones
 - 84:04.08.28 - Polyenes
 - 84:04.08.32 - Pyrimidines*
 - 84:04.08.40 - Thiocarbamates
 - 84:04.08.92 - Antifungals, Miscellaneous
 - 84:04.12 - Scabicides and Pediculicides
 - 84:04.92 - Local Anti-infectives, Miscellaneous
- 84:06 - Anti-inflammatory Agents**
- 84:08 - Antipruritics and Local Anesthetics**
- 84:12 - Astringents***
- 84:16 - Cell Stimulants and Proliferants**
- 84:20 - Detergents§**
- 84:24 - Emollients, Demulcents, and Protectants§**
 - 84:24.04 - Basic Lotions and Liniments*
 - 84:24.08 - Basic Oils and Other Solvents*
 - 84:24.12 - Basic Ointments and Protectants*
 - 84:24.16 - Basic Powders and Demulcents*
- 84:28 - Keratolytic Agents**
- 84:32 - Keratoplastic Agents**
- 84:50 - Depigmenting and Pigmenting Agents§**
 - 84:50.04 - Depigmenting Agents§
 - 84:50.06 - Pigmenting Agents§
- 84:80 - Sunscreen Agents§**
- 84:92 - Skin and Mucous Membrane Agents, Miscellaneous**

- 86:00 - Smooth Muscle Relaxants**
 - 86:08 - Gastrointestinal Smooth Muscle Relaxants*
 - 86:12 - Genitourinary Smooth Muscle Relaxants
 - 86:16 - Respiratory Smooth Muscle Relaxants

- 88:00 - Vitamins**
 - 88:04 - Vitamin A§
 - 88:08 - Vitamin B Complex§
 - 88:12 - Vitamin C§
 - 88:16 - Vitamin D§
 - 88:20 - Vitamin E§
 - 88:24 - Vitamin K Activity
 - 88:28 - Multivitamin Preparations§

- 92:00 - Miscellaneous Therapeutic Agents**
 - Alcohol Deterrents
 - 5- α -Reductase Inhibitors
 - Antidotes



AHFS Classification

Antigout Agents
Antiparkinsonian Agents
Biologic Response Modifiers
Bone Resorption Inhibitors
Cariostatic Agents§
Complement Inhibitors
Disease-Modifying Antirheumatic Agents
Gonadotropin-releasing Hormone
Antagonists
Immunosuppressive Agents
Protective Agents
Other Miscellaneous Therapeutic Agents

94:00 - Devices*

96:00 - Pharmaceutical Aids*

* Category is currently not in use in the printed version of *AHFS Drug Information*.

§ Omitted from the print version of *AHFS Drug Information* because of space limitations. Copies of these monographs are available on the *AHFS Drug Information* web site, <http://www.ahfsdruginformation.com>. See the Preface for details on accessing this site.



ARNNL is the professional organization representing all 6300 Registered Nurses and 90 Nurse Practitioners in the province. In pursuit of its vision, “Healthy People in Newfoundland and Labrador,” ARNNL exists so there will be excellence in nursing, public protection, quality health care, and healthy public policy.

Association of Registered Nurses of Newfoundland and Labrador
55 Military Road, St. John's, NL. A1C 2C5
Web Site: www.arannl.ca, Email: info@arannl.ca
Telephone: 709-753-6040, Toll Free: 800-563-3200
Facsimile: 709 753 4940